Objective 
Introduction

The number of patients requiring dialysis due to diabetic nephropathy (DN) is increasing year by year in Japan, and it has currently become the number one reason for starting dialysis, followed by chronic glomerulonephritis. The mechanisms leading to the onset and progression of DN should be urgently clarified in order to improve the quality of life of patients with renal failure and to reduce medical costs. The relationship between podocyte damage and renal disease has attracted attention in recent years and reports about involvement of podocyte loss in the progression of DN have been published
. The association of podocyte hypertrophy with podocyte loss has also been reported (6, 7) , however, this relationship has not been examined in detail using human DN renal tissues.
Recently, some podocyte specific proteins have been reported. The Wilm's tumor-1 (WT1) gene encodes the WT1 protein, which is expressed throughout urogenital development and continues to be highly expressed in podocytes.
Furthermore, WT1 may play an important role in the maintenance of podocyte function (8, 9) . On the other hand, synaptopodin (SPD) is a proline-rich protein, intimately associated with the actin microfilament, and it is exclusively expressed in the foot process of podocytes (10) . While SPD is expressed in the foot processes, WT1 is exclusively expressed in the nucleus of the podocyte. A recent study using an experimental diabetic rat model reported down regulation in both WT1 and SPD rats compared with normal condition rats, and these results may be related podocyte loss (11) .
In the present study, we aimed to clarify the relationship between podocyte loss and podocyte hypertrophy based on various clinical indexes and immunostaining of human DN T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s b e t we e n DN a n d Co n t r o l renal tissues for WT1 and SPD, which are different distribution markers of podocytes.
Subjects and Methods
Patients
The subjects were 17 
Results
Podocytes were identified by immunostaining for WT1 and SPD (Fig. 1) . The number of WT1-positive/SPDpositive cells (podocyte count) was significantly decreased in DN patients compared with the controls (Figs. 3, 4 ). An inverse correlation was observed between the number of WT 1-positive/SPD-positive cells and U-Prot (Fig. 5A) . There was no significant correlation between the number of WT1-positive/SPD-positive cells and Ccr (Fig. 5B ). An inverse correlation was observed between the number of WT1- I mmu n o h i s t o c h e mi s t r y o f WT 1 a n d S P D d o u b l e s t a i n i n g . ( A) WT 1 s t a i n i n g s h o we d a  n u c l e a r p a t t e r n a n d S P D s t a i n i n g s h o we d a l i n e a r p a t t e r n ( o r i g i n a l ma g n i f i c a t i o n × 1 0 0 ) 
. ( B ) WT 1 -p o s i t i v e c e l l s , l o c a t e d i n t h e S P D-p o s i t i v e a r e a o r p r o x i ma l t o t h e u r i n a r y s p a c e , we r e d e f i n e d a s p od o c y t e s ( a r r o w, × 2 0 0 ) .
F i g u r e 2 . T h e c a l c u l a t i o n me t h o d o f t h e S P D-p o s i t i v e a r e a . T h e e x p r e s s i o n l e v e l o f s y n a p t o p o d i n p r o t e i n wa s q u a n t i t a t e d b y p e r c e n t a g e o f i mmmu n o h i s t o c h e mi c a l l y -p o s i t i v e a r e a i n a g l o me r u l u s [ ( A) / ( B ) × 1 0 0 , wh e r e ( A) i s t h e i mmmu n o h i s t o c h e mi c a l l y -p o s i t i v e a r e a i n t h e g l o me r u l u s a n d ( B ) i s t h e t o t a l a r e a o f t h e g l o me r u l u s ] . F i n a l l y , S P D-p o s i t i v e a r e a p e r t h e n u mb e r o f WT 1 -p o s i t i v e / S P Dp o s i t i v e c e l l s ( n u mb e r o f p o d o c y t e s ) wa s c a l c u l a t e d a s a n i n d e x o f p o d o c y t e h y p e r t r o p h y .
F i g u r e 3 . I mmu n o h i s t o c h e mi s t r y o f WT 1 a n d S P D d o u b l e s t a i n i n g i n DN ( A) a n d c o n t r o l ( B ) .
positive/SPD-positive cells and the PAS-positive area (Fig. 5C). The ratio of the SPD-positive area to the number of WT1-positive/SPD-positive cells, an index for evaluating hypertrophy of podocytes, was significantly increased in DN
F i g u r e 4 . T h e n u mb e r o f WT 1 -p o s i t i v e / S P D-p o s i t i v e c e l l s ( p o d o c y t e ) wa s d e c r e a s e d i n DN c o mp a r e d wi t h t h e c o n t r o l .
F i g u r e 5 . ( A) Co r r e l a t i o n b e t we e n t h e n u mb e r o f WT 1 -p o s i t i v e / S P D-p o s i t i v e c e l l s a n d u -p r o t . ( B ) Co r r e l a t i o n b e t we e n t h e n u mb e r o f WT 1 -p o s i t i v e / S P D-p o s i t i v e c e l l s a n d Cc r . ( C) Co r r e l a t i o n b e t we e n t h e n u mb e r o f WT 1 -p o s i t i v e / S P D-p o s i t i v e c e l l s a n d P AS -p o s i t i v e a r e a .
patients (Fig. 6 ).
Discussion
In (20) . Further assessment of the above reports is necessary to determine whether podocyte loss and podocyte hypertrophy is the cause or result. The patients with DN in this study had overt nephropathy rather than microalbuminuria, and both podocyte loss and
F i g u r e 6 . T h e r a t i o o f t h e S P D-p o s i t i v e a r e a t o t h e n u mb e r o f WT 1 -p o s i t i v e / S P D-p o s i t i v e c e l l s ( p o d o c y t e h y p e r t r o p h y ) i n DN c o mp a r e d wi t h t h e c o n t r o l .
T a b l e 2 . Di f f e r e n c e s b e t we e n ACE -I s / ARB s P r e s c r i b e d Gr o u p a n d n o t P r e s c r i 
